NEUROCRINE Aktie

>NEUROCRINE Aktienkurs

119.325 EUR (Tradegate)

Ask: 119.95 EUR / 41 Stück

Bid: 118.7 EUR / 42 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

NEUROCRINE Aktie über LYNX handeln

Intraday

1 Jahr

>NEUROCRINE Performance

1 Woche: +2,4%

1 Monat: +2,5%

3 Monate: +9,4%

6 Monate: +5,1%

1 Jahr: +2,5%

laufendes Jahr: -10,2%

>NEUROCRINE Aktie

Name:

NEUROCRINE BIOSCI. DL-001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US64125C1099 / 900964

Symbol/ Ticker:

NB3 (Frankfurt) / NBIX (NASDAQ)

Kürzel:

FRA:NB3, ETR:NB3, NB3:GR, NASDAQ:NBIX

Index:

Webseite:

http://www.neurocrine.com..

Profil:

Neurocrine Biosciences Inc. is a biopharmaceutical..
>Volltext..

Marktkapitalisierung:

11848.9 Mio. EUR

Unternehmenswert:

11436.81 Mio. EUR

Umsatz:

2147.92 Mio. EUR

EBITDA:

451.51 Mio. EUR

Nettogewinn:

298.07 Mio. EUR

Gewinn je Aktie:

2.98 EUR

Schulden:

419.16 Mio. EUR

Liquide Mittel:

225.93 Mio. EUR

Operativer Cashflow:

485.48 Mio. EUR

Bargeldquote:

1.79

Umsatzwachstum:

7.68%

Gewinnwachstum:

-6.63%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 13.440.281 USD.

Suchwörter:

NEUROCRINE

Letzte Datenerhebung:

31.08.25

>NEUROCRINE Kennzahlen

Aktien/ Unternehmen:

Aktien: 99.18 Mio. St.

Frei handelbar: 97.29%

Leerverk. Aktien: 4%

Rückkaufquote: 2.78%

Mitarbeiter: 1800

Umsatz/Mitarb.: 1.12 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 21.07%

Bewertung:

KGV: 41.29

KGV lG: 30.5

KUV: 5.56

KBV: 5.14

PEG-Ratio: 17.41

EV/EBITDA: 25.33

Rentabilität:

Bruttomarge: 98.02%

Gewinnmarge: 13.88%

Operative Marge: 19.89%

Managementeffizenz:

Gesamtkaprendite: 9.68%

Eigenkaprendite: 13.39%

>NEUROCRINE Peer Group

Es sind 601 Aktien bekannt.

>NEUROCRINE Chart & Kurs - NASDAQ

>NEUROCRINE News

26.08.25 - 22:03	Neurocrine Biosciences to Present at Upcoming Investor Conferences in September (PR Newswire)
	SAN DIEGO, Aug. 26, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at four investor conferences in September. Chief Financial Officer Matt Abernethy, Chief Commercial Officer Eric Benevich, and Vice-President of Investor Relations Todd Tushla will......

12.08.25 - 04:01	Insiderhandel: Aufsichtsrat verkauft Aktien von Neurocrine Biosciences im Wert von 13440281 USD (Insiderkauf)
	Gorman, Kevin Charles - Aufsichtsrat - Tag der Transaktion: 2025-08-07...

06.08.25 - 22:03	Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference (PR Newswire)
	SAN DIEGO, Aug. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Canaccord Genuity 45th Annual Growth Conference at 8:00 a.m. ET on Wednesday, August 13, 2025. Chief Executive Officer Kyle Gano and Vice-President of Investor Relations Todd Tushla......

05.08.25 - 07:00	Neurocrine (NBIX) Q2 2025 Earnings Call Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

01.08.25 - 06:48	Neurocrine (NBIX) Q2 Revenue Jumps 17% (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

31.07.25 - 22:21	The Analyst Verdict: Neurocrine Biosciences In The Eyes Of 17 Experts (Benzinga)
	Latest Ratings for NBIX DateFirmActionFromTo Mar 2022Piper SandlerDowngradesOverweightNeutral Feb 2022Goldman SachsUpgradesNeutralBuy Feb 2022Morgan StanleyMaintainsEqual-Weight View More Analyst Ratings for NBIX View the Latest Analyst Ratings read more...

31.07.25 - 02:21	Neurocrine refines INGREZZA net sales guidance to $2.5B-$2.55B while CRENESSITY surges, driving revenue growth and pipeline expansion (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

30.07.25 - 23:30	Neurocrine Biosciences Inc Q2 Profit Increases, Beats Estimates (AFX)
	WASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc (NBIX) announced a profit for its second quarter that Increased from the same period last year and beat the Street estimates.The company's bottom ......

30.07.25 - 22:06	Neurocrine Biosciences Non-GAAP EPS of $1.65 beats by $0.18, revenue of $687.5M beats by $35.75M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

30.07.25 - 22:03	Neurocrine Biosciences Reports Second Quarter 2025 Financial Results (PR Newswire)
	Achieved Total Net Product Sales of $682 Million Representing 17% Year-Over-Year Growth INGREZZA® (valbenazine) Second-Quarter 2025 Net Product Sales of $624 Million and Narrows 2025 Net Product Sales Guidance to $2.5 - $2.55 Billion CRENESSITY® (crinecerfont) Second-Quarter 2025 Net......

23.07.25 - 17:30	Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week′s Release (Zacks)
	Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

15.07.25 - 15:03	Neurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition (PR Newswire)
	Technology-enabled research approach and AI-powered analysis identify unmet needs in patients with congenital adrenal hyperplasia SAN FRANCISCO, July 15, 2025 /PRNewswire/ -- PicnicHealth, a health technology company dedicated to advancing the next generation of non-interventional......

15.07.25 - 14:33	Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025 (PR Newswire)
	Approximately 95% of adult and pediatric patients were exposed to supraphysiologic doses of glucocorticoids and/or experienced elevated androstenedione levels at least once during their treatment journey Real-world findings underscore long-term challenges of managing classic congenital......

15.07.25 - 04:54	NBIX: Phase 3 Study Shows CRENESSITY Improves Weight-Related Outcomes In Adrenal Disorder Patients (AFX)
	WASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc. (NBIX) shared new results from a one-year clinical study at the Endocrine Society's 2025 Annual Meeting in San Francisco. The study looked at bot......

14.07.25 - 22:36	Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society′s Annual Meeting (PR Newswire)
	Adult and pediatric patients with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont) achieved clinically meaningful weight reductions Substantial improvements in insulin resistance were also observed in both adult and pediatric patients treated with CRENESSITY......

14.07.25 - 16:24	Neurocrine Biosciences Reports Positive 1-year Data Of Crenessity In Adults With CAH At ENDO 2025 (AFX)
	WASHINGTON (dpa-AFX) - Neurocrine Biosciences, Inc. (NBIX) Monday reported new positive data from the Phase 3 CAHtalyst Adult study of Crenessity in adults with classic congenital adrenal hyperpla......

14.07.25 - 15:42	Neurocrine reports positive results from Crenessity trial (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.07.25 - 14:33	Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025 (PR Newswire)
	One-year data from CAHtalyst™ Adult study demonstrated lasting reductions in glucocorticoid dose and improvement in clinical outcomes in adults with classic congenital adrenal hyperplasia Results build upon previously reported one-year data from CAHtalyst™ Pediatric study SAN DIEGO, July......

12.07.25 - 00:01	Insiderhandel: Chief Regulatory Officer verkauft Aktien von Neurocrine Biosciences im Wert von 61695 USD (Insiderkauf)
	Delaet, Ingrid - Vorstand - Tag der Transaktion: 2025-07-10...

12.07.25 - 00:01	Insiderhandel: Chief Scientific Officer verkauft Aktien von Neurocrine Biosciences im Wert von 7803688 USD (Insiderkauf)
	Onyia, Jude - Vorstand - Tag der Transaktion: 2025-07-09...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Der Humorist lustwandelt innerhalb der Unendlichkeit. - Arthur Schnitzler

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram